Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Clarus Corporation - Common Stock (NQ:CLAR)

3.390 -0.220 (-6.09%)
Streaming Delayed Price Updated: 12:58 PM EDT, Apr 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Clarus Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Clarus Sets Third Quarter 2023 Conference Call for Tuesday, November 7, 2023, at 5:00 p.m. ET
From Clarus Corporation
Via GlobeNewswire
Clarus Acquires TRED Outdoors, a Fast-Growing Outdoor Adventure Brand
From Clarus Corporation
Via GlobeNewswire
Special Committee of Clarus Retains Houlihan Lokey as Financial Advisor
From Clarus Corporation
Via GlobeNewswire
Analyst Ratings for Clarus
Via Benzinga
Clarus's Ex-Dividend Date Is Friday, Here's What You Need To Know
Via Benzinga
Earnings Preview: Clarus
Via Benzinga
Expert Ratings for Clarus
Via Benzinga
Clarus Confirms Receipt of Non-Binding Indication of Interest Regarding Precision Sport Segment
From Clarus Corporation
Via GlobeNewswire
12 Consumer Discretionary Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Fostering Confidence: Clarus Reliable Progress and Investor Expectations
Today, August 25, 2023, marks an important moment for investors of Clarus (NASDAQ:CLAR). The company will distribute a dividend payout of $0.03 per share, demonstrating an annualized dividend yield of... 
Via Benzinga
12 Consumer Discretionary Stocks Moving In Monday's After-Market Session
Via Benzinga
What 4 Analyst Ratings Have To Say About Clarus
Via Benzinga
Clarus: Dividend Insights
Via Benzinga
Clarus Earnings Preview
Via Benzinga
Why 22nd Century Group Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) shares jumped 283.7% to $1.3007 after Harmony Biosciences entered into definitive agreement to acquire the company for total potential consideration... 
Via Benzinga
Clarus Reports Second Quarter 2023 Results
From Clarus Corporation
Via GlobeNewswire
Clarus's Return On Capital Employed Insights
Via Benzinga
Friday Is Your Last Chance To Buy Clarus Before The Dividend Payout
Via Benzinga
Clarus Announces $0.025 Per Share Quarterly Dividend
From Clarus Corporation
Via GlobeNewswire
Clarus Sets Second Quarter 2023 Conference Call for Monday, August 7, 2023, at 5:00 p.m. ET
From Clarus Corporation
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For June 29, 2023
Via Benzinga
Clarus Announces June Investor Conference Schedule
From Clarus Corporation
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For May 3, 2023
Via Benzinga
Clarus Reports First Quarter 2023 Results
From Clarus Corporation
Via GlobeNewswire
Earnings Scheduled For May 1, 2023
Companies Reporting Before The Bell • TG Therapeutics (NASDAQ:TGTX) is estimated to report quarterly loss at $0.37 per share on revenue of $3.38 million. 
Via Benzinga
Clarus Announces $0.025 Per Share Quarterly Dividend
From Clarus Corporation
Via GlobeNewswire
Clarus Sets First Quarter 2023 Conference Call for Monday, May 1, 2023, at 5:00 p.m. ET
From Clarus Corporation
Via GlobeNewswire
10 Consumer Discretionary Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Clarus Announces March Investor Conference Schedule
From Clarus Corporation
Via GlobeNewswire
12 Consumer Discretionary Stocks Moving In Monday's After-Market Session
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.